Omeros Begins Enrollment In Phase 2 Clinical Trial With OMS824 - Quick Facts

(RTTNews) - Omeros Corp. (OMER) Thursday said it initiated enrollment in its phosphodiesterase 10 or PDE10 inhibitor OMS824's Phase 2 clinical trial. The trial will evaluate the compound's tolerability, safety, pharmacokinetics, potential interactions with concomitant antipsychotic medications, and cognitive tests in patients with stable schizophrenia. PDE10 is an enzyme that is expressed in areas of the brain linked to diseases that affect cognition and psychomotor functions, including Huntington's disease and schizophrenia. The company said the safety and any efficacy findings in the Phase 1 trial are planned for use in determining appropriate dosing regimens and selecting endpoints for subsequent Phase 2 and Phase 3 clinical trials in schizophrenia.

"This Phase 2 trial will provide us with important information on our compound's safety and, potentially, efficacy for additional Phase 2 trials in schizophrenia and Huntington's disease. We look forward to completing the current trial later this year." said Gregory Demopulos, M.D., chairman and chief executive officer of Omeros.